|Bid||83.33 x 400|
|Ask||85.07 x 100|
|Day's Range||82.84 - 84.76|
|52 Week Range||64.18 - 86.72|
|PE Ratio (TTM)||40.77|
|Dividend & Yield||2.08 (2.52%)|
|1y Target Est||N/A|
Health care stocks got a lift Thursday after Senate Republicans rolled out their proposed bill to repeal Obamacare.
On June 8, 2017, Eli Lilly (LLY) announced a strategic collaboration with KeyBioscience AG to focus on the development of dual amylin calcitonin receptor agonists (or DACRAs).
Jardiance (empagliflozin) is a part of the Boehringer Ingelheim and Eli Lilly’s (LLY) diabetes alliance.